Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer
Economic impact of diagnostic testing
8 evidence topics · 10 sources
Medicare payment for liquid biopsy and tissue genomic sequencing panels, Clinical Laboratory Fee Schedule fourth-quarter file
| Code | Short description in the file | Rate in the file (U.S. dollars) |
|---|---|---|
| 0242U | “Trgt gen seq alys pnl 55-74” | “05000.00” |
| 0239U | “Trgt gen seq alys pnl 311+” | “03500.00” |
| 0326U | “Trgt gen seq alys pnl 83+” | “05000.00” |
| 81455 | “So/hl 51/>gsap dna/dna&rna” | “02919.60” |
Advanced Diagnostic Laboratory Test status and initial-period payment for Guardant360 CDx and FoundationOne Liquid CDx
| Test code | Laboratory | Test name | Payment amount during new ADLT initial period |
|---|---|---|---|
| 0242U | “Guardant Health, Inc.” | “Guardant360 CDx” | “$5,000.00” |
| 0239U | “Foundation Medicine, Inc.” | “FoundationOne Liquid CDx” | “$3,500.00” |
Medicare national coverage of next-generation sequencing companion diagnostics in advanced cancer
State biomarker testing insurance coverage laws
“Cost and lack of insurance coverage are common barriers to testing because insurance coverage varies across commercial payers, Medicare, and Medicaid.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen states have passed legislation related to biomarker testing since 2021” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All laws apply to commercial payers; in 12 states, the laws also apply to Medicaid.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most laws (n = 11) require coverage of biomarker testing broadly without regard to condition. Four states (Arkansas, California, Louisiana, and Nevada) specify coverage of cancer biomarkers, with California specifying coverage for testing for stage III or IV cancer only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Managed care perspectives on ESR1 and circulating tumor DNA testing costs and coverage
“Key insight: A primary consideration of payers in aBC is that the optimal biomarker testing parameters are uncertain, which leads to inconsistent testing practices and the need for management that promotes consistency while mitigating delays in care such as via treatment pathways.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants also recognized that although the cost of additional biomarker testing may not be realized by the provider or patient, it could be a cost-of-care consideration for payers including employer groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Payer participants expressed concern with regular, potentially costly testing if it does not result in actionable information for making treatment decisions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Coverage and out-of-pocket cost barriers to next-generation sequencing reported by US stakeholders in metastatic breast cancer
“This study revealed that despite the awareness and recognition of the value proposition of NGS-based molecular profiling in mBC, inconsistent payer coverage, high out of pocket costs for patients, and challenges in managing reimbursement and prior authorization processes can lead to suboptimal utilization of NGS, which can subsequently lead to suboptimal treatment decisions where approved therapies exist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Interestingly, many payers (33%) were not aware of the current somatic biomarker testing recommendations from NCCN guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ESR1 testing rates by line of therapy in US practice
“Testing rates at 1L initiation were 36.2% in endocrine-resistant MBC and 19.6% in endocrine-sensitive/de novo MBC. Testing rates were approximately 32% at second line and 25% at third line across subgroups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Specimen type and turnaround time of ESR1 tests during first-line therapy in US practice
“Among 7772 patients with mBC in the FHRD who initiated 1 L therapy, tumor ESR1 mutation status was evaluated for 222 (3%) patients at baseline (≤ 90 days before 1 L) and 1355 (17%) during 1 L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most (60%) tests during 1 L used tissue specimens, while the remaining 40% were liquid biopsies, and the median time from specimen collection to result reporting in 1 L was 28 (IQR:10–84) days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote